Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Immunome Inc (NQ: IMNM )

13.54 -0.68 (-4.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunome Inc

< Previous 1 2 3 4 5 6 Next >
Immunome Announces Pricing of Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Immunome Announces Proposed Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Immunome, Inc.
Via Business Wire
Immunome Inc. (NASDAQ: IMNM) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Exposures COVID-19
Why Are Immunome Shares Trading Higher Today
Immunome Inc (NASDAQ: IMNM) and Morphimmune have announced a merger agreement in  
Via Benzinga
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile 
From Ayala Pharmaceuticals
Via GlobeNewswire
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Immunome, Inc.
Via Business Wire
Immunome - Oncology Is Hot
Immunome, an oncology biomedical company, has gained 27.48% since a buy signal on December 22. 
Via Talk Markets
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
From Immunome, Inc.
Via Business Wire
Immunome Appoints Phil Roberts as Chief Technical Officer
From Immunome, Inc.
Via Business Wire
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Appoints Carol A. Schafer to Board of Directors
From Immunome, Inc.
Via Business Wire
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
From Immunome, Inc.
Via Business Wire
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
From Atreca, Inc.
Via GlobeNewswire
Immunome to Present at the Stifel 2023 Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Third Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
From Immunome, Inc.
Via Business Wire
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
From Immunome, Inc.
Via Business Wire
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
From Immunome, Inc.
Via Business Wire
Immunome Reports Second Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Nasdaq Moves Lower; Acuity Brands Earnings Top Estimates
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow traded up 0.68% to 34,081.83 while the NASDAQ fell 0.23% to 13,560.57. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash. 
Via Benzinga
IMNM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Immunome, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Immunome (NASDAQ: IMNM) and Morphimmune Announce Merger to Develop Best-in-Class Targeted Cancer Therapies
Via Spotlight Growth
Exposures Product Safety
Dow Rises Over 100 Points; US GDP Grows 2% In Q1
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.37% to 33,977.04 while the NASDAQ rose... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
From Immunome
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.